| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NOK; SuRTK106 |
| WB Predicted band size | 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human STYK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于STYK1抗体的3篇假设文献示例(注：以下内容为虚构，仅用于示例)：
1. **文献名称**：*"Development of a monoclonal antibody targeting STYK1 for functional analysis in breast cancer models"*
**作者**：Zhang Y, et al.
**摘要**：本研究开发了一种高特异性抗人STYK1单克隆抗体，验证了其在乳腺癌细胞系中通过抑制STYK1激酶活性降低肿瘤细胞增殖和迁移的能力，为靶向治疗提供潜在工具。
2. **文献名称**：*"STYK1 overexpression in non-small cell lung cancer detected by novel polyclonal antibody: Clinical correlations"*
**作者**：Li H, et al.
**摘要**：通过制备兔源多克隆抗体，研究者证实STYK1在肺癌组织中的异常高表达与患者预后不良相关，抗体可用于免疫组化检测及分子机制研究。
3. **文献名称**：*"STYK1 antibody-based inhibition suppresses epithelial-mesenchymal transition in colorectal cancer cells"*
**作者**：Wang J, et al.
**摘要**：利用新型STYK1中和抗体阻断其信号通路，发现可显著抑制结直肠癌细胞上皮-间质转化(EMT)，提示抗体在抗转移治疗中的应用潜力。
(注：实际文献需通过PubMed/Google Scholar等平台以“STYK1 antibody”“STYK1 kinase”等关键词检索。)
STYK1 (Serine/Threonine/Tyrosine Kinase 1), also known as NOK or MST3. is a member of the protein kinase superfamily, characterized by its dual-specificity kinase activity. Structurally, it contains a conserved kinase domain but lacks extracellular and transmembrane regions, distinguishing it from typical receptor tyrosine kinases. STYK1 is implicated in regulating cellular processes such as proliferation, apoptosis, and migration, primarily through phosphorylation-mediated signaling pathways. Its overexpression has been observed in various cancers, including breast, lung, and liver carcinomas, where it correlates with tumor growth, metastasis, and poor prognosis. However, its exact physiological and pathological mechanisms remain incompletely understood, partly due to the absence of a known specific ligand or upstream regulators.
STYK1 antibodies are essential tools for studying its expression, localization, and function in both normal and diseased tissues. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels and subcellular distribution. Commercially available antibodies target specific epitopes, often within the kinase domain, but validation is crucial due to potential cross-reactivity with homologous kinases. Research using these antibodies has highlighted STYK1's potential as a therapeutic target, though drug development is still in early stages. Challenges include clarifying its signaling network and resolving conflicting findings across studies. Continued investigation of STYK1 and its antibodies may advance cancer diagnostics and kinase-targeted therapies.
×
